Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    EUR1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

    Sareum Holdings

    MCap

    GBP13m

    Last close

    GBP0.15

    ▲ 1.75 (13.73%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive Interview – PsiOxus

Executive Interview – PsiOxus

PsiOxus Therapeutics is an Oxford-based immunotherapy company that has developed a tumour-targeted delivery platform based on its lead oncolytic vaccine, Enadenotucirev (formerly ColoAd1). Enadenotucirev is an oncolytic virus that selectively kills cancer cells by lysis and is currently being studied in four clinical trials in various cancer indications. Under the PsiOxus collaboration with Bristol Myers Squibb, a Phase I combination study of Enadenotucirev with checkpoint inhibitor nivolumab (Opdivo) in a range of tumours, is due to start in Q316. PsiOxus also has a next-generation platform (T-SIGn Therapy) in development. This platform enables the anti-tumour effect of Enadenotucirev to be expanded through the addition of new genes (‘Armed EnAd’) creating a broad range of unique oncolytic immune therapeutics. NG-348, the first product candidate to emerge from this platform, will start Phase I in 2017.

< Previous
Next >

You may also be interested in these:

Investment Companies

IP Group - executive interview

Investment Companies

Oakley Capital Investments – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free